Background: Celastrol is an active ingredient extracted from Traditional Chinese Medicine (TCM), which can restrain the progression of lung cancer, whereas its underlying mechanism is unclear. In our study, the underlying mechanism of celastrol in the treatment of lung adenocarcinoma (LUAD) with metastasis was investigated by network pharmacology and molecular docking. Method: Potential targets of celastrol were collected from TCMSP, Batman-TCM and GeneCard database, and its potential targets were predicted using the STP platform and the TargetNet server. Metastasis marker genes (MGs) were obtained from the HCMDB. The genes correlated with LUAD were gathered from the GeneCard and OMIM database. And the common targets among celastrol potential targets, MGs and LUAD were analyzed. The protein-protein interaction (PPI) networks were obtained from the STRING database. SangerBox and the Xiantao bioinformatics tool were applied to visualize GO and KEGG analysis. Molecular docking tested the binding affinity between celastrol and core genes. Result: A total of 107 targets of celastrol against metastasis LUAD were obtained. The core targets were obtained from the PPI network, namely AKT1, JUN, MYC, STAT3, IL6, TNF, NFKB1, BCL2, IL1B, and HIF1A. GO and KEGG enrichment analysis indicated celastrol for the treatment of metastasis LUAD most refers to cellular response to chemical stress, DNA-binding transcription factor binding, transcription regulator complex and pathways in cancer. And some of these targets are associated with differential expressions and survival rates in LUAD. Moreover, Molecular docking shows celastrol can bind with BCL2 well by hydrogen bond and hydrophobic interaction. Conclusion: This finding roundly expounded the core genes and potential mechanisms of celastrol for the treatment of metastasis LUAD, offering the theoretical basis and antitumor mechanism of TCM in the treatment of lung cancer.
References
[1]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
De Goede, O.M., Nachun, D.C., Ferraro, N.M., et al. (2021) Population-Scale Tissue Transcriptomics Maps Long Non-Coding RNAs to Complex Disease. Cell, 184, 2633-2648.E19. https://doi.org/10.1016/j.cell.2021.03.050
[3]
Zappa, C. and Mousa, S.A. (2016) Non-Small Cell Lung Cancer: Current Treatment and Future Advances. Translational Lung Cancer Research, 5, 288-300. https://doi.org/10.21037/tlcr.2016.06.07
[4]
Subramanian, J. and Govindan, R. (2007) Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology, 25, 561-570. https://doi.org/10.1200/jco.2006.06.8015
[5]
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., et al. (2022) Immune Checkpoint Modulators in Cancer Immunotherapy: Recent Advances and Emerging Concepts. Journal of Hematology & Oncology, 15, Article No. 111. https://doi.org/10.1186/s13045-022-01325-0
[6]
Kennedy, K., Hulbert, A., Pasquinelli, M. and Feldman, L.E. (2022) Impact of CT Screening in Lung Cancer: Scientific Evidence and Literature Review. Seminars in Oncology, 49, 198-205. https://doi.org/10.1053/j.seminoncol.2022.06.013
[7]
Chen, V.W., Ruiz, B.A., Hsieh, M., Wu, X., Ries, L.A.G. and Lewis, D.R. (2014) Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer from SEER Registries: AJCC Staging and Collaborative Stage Data Collection System. Cancer, 120, 3781-3792. https://doi.org/10.1002/cncr.29045
[8]
Tuorkey, M.J. (2015) Cancer Therapy with Phytochemicals: Present and Future Perspectives. Biomedical and Environmental Sciences, 28, 808-819. https://doi.org/10.1016/s0895-3988(15)30111-2
[9]
Chen, S., Dai, Y., Zhao, J., Lin, L., Wang, Y. and Wang, Y. (2018) A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F. Frontiers in Pharmacology, 9, Article 104. https://doi.org/10.3389/fphar.2018.00104
[10]
Ma, X., Xu, L., Alberobello, A.T., Gavrilova, O., Bagattin, A., Skarulis, M., et al. (2015) Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1α Transcriptional Axis. Cell Metabolism, 22, 695-708. https://doi.org/10.1016/j.cmet.2015.08.005
[11]
Xu, X. (2003) Observation on Serum Anti-Double Stranded DNA Antibodies of Tripterine in Systemic Lupus Erythematosus of (NZB×W) F1 Mice. Annals of the Rheumatic Diseases, 62, 377-377. https://doi.org/10.1136/ard.62.4.377
[12]
Yuan, Z., Wang, J., Qu, Q., Zhu, Z., Xu, M., Zhao, M., et al. (2023) Celastrol Combats Methicillin‐Resistant Staphylococcus aureus by Targeting Δ1‐Pyrroline‐5‐Carboxylate Dehydrogenase. Advanced Science, 10, Article 2302459. https://doi.org/10.1002/advs.202302459
[13]
Zhao, Q., Dai, M., Huang, R., Duan, J., Zhang, T., Bao, W., et al. (2023) Parabacteroides distasonis Ameliorates Hepatic Fibrosis Potentially via Modulating Intestinal Bile Acid Metabolism and Hepatocyte Pyroptosis in Male Mice. Nature Communications, 14, Article No. 1829. https://doi.org/10.1038/s41467-023-37459-z
[14]
Kashyap, D., Sharma, A., Tuli, H.S., Sak, K., Mukherjee, T. and Bishayee, A. (2018) Molecular Targets of Celastrol in Cancer: Recent Trends and Advancements. Critical Reviews in Oncology/Hematology, 128, 70-81. https://doi.org/10.1016/j.critrevonc.2018.05.019
[15]
Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., et al. (2023) Celastrol Suppresses Colorectal Cancer via Covalent Targeting Peroxiredoxin 1. Signal Transduction and Targeted Therapy, 8, Article No. 51. https://doi.org/10.1038/s41392-022-01231-4
[16]
Uttarkar, S., Dassé, E., Coulibaly, A., Steinmann, S., Jakobs, A., Schomburg, C., et al. (2016) Targeting Acute Myeloid Leukemia with a Small Molecule Inhibitor of the Myb/p300 Interaction. Blood, 127, 1173-1182. https://doi.org/10.1182/blood-2015-09-668632
[17]
Chen, X., Zhao, Y., Luo, W., Chen, S., Lin, F., Zhang, X., et al. (2020) Celastrol Induces ROS-Mediated Apoptosis via Directly Targeting Peroxiredoxin-2 in Gastric Cancer Cells. Theranostics, 10, 10290-10308. https://doi.org/10.7150/thno.46728
[18]
Yan, Y., Zhang, H., Lv, Q., Liu, Y., Li, Y., Li, B., et al. (2017) Celastrol Suppresses the Proliferation of Lung Adenocarcinoma Cells by Regulating microRNA-24 and microRNA-181b. Oncology Letters, 15, 2515-2521. https://doi.org/10.3892/ol.2017.7593
[19]
Liu, P., Wang, M., Tang, W., Li, G. and Gong, N. (2020) Circ_SATB2 Attenuates the Anti-Tumor Role of Celastrol in Non-Small-Cell Lung Carcinoma through Targeting miR-33a-5p/E2F7 Axis. OncoTargets and Therapy, 13, 11899-11912. https://doi.org/10.2147/ott.s279434
[20]
Mou, H., Zheng, Y., Zhao, P., Bao, H., Fang, W. and Xu, N. (2011) Celastrol Induces Apoptosis in Non-Small-Cell Lung Cancer A549 Cells through Activation of Mitochondria-and Fas/FasL-Mediated Pathways. Toxicology in Vitro, 25, 1027-1032. https://doi.org/10.1016/j.tiv.2011.03.023
[21]
Lee, Y., Kim, S. and Lee, C. (2019) Axl Is a Novel Target of Celastrol That Inhibits Cell Proliferation and Migration, and Increases the Cytotoxicity of Gefitinib in EGFR Mutant Non-Small Cell Lung Cancer Cells. Molecular Medicine Reports, 19, 3230-3236. https://doi.org/10.3892/mmr.2019.9957
[22]
Lee, J.-H., Choi, K.J., Seo, W.D., Jang, S.Y., Kim, M., Lee, B.W., et al. (2011) Enhancement of Radiation Sensitivity in Lung Cancer Cells by Celastrol Is Mediated by Inhibition of Hsp90. International Journal of Molecular Medicine, 27, 441-446. https://doi.org/10.3892/ijmm.2011.601
[23]
Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., et al. (2014) TCMSP: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines. Journal of Cheminformatics, 6, Article No. 13. https://doi.org/10.1186/1758-2946-6-13
[24]
Liu, Z., Guo, F., Wang, Y., Li, C., Zhang, X., Li, H., et al. (2016) BATMAN-TCM: A Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine. Scientific Reports, 6, Article No. 21146. https://doi.org/10.1038/srep21146
[25]
Safran, M., Dalah, I., Alexander, J., Rosen, N., Iny Stein, T., Shmoish, M., et al. (2010) GeneCards Version 3: The Human Gene Integrator. Database, 2010, baq020. https://doi.org/10.1093/database/baq020
[26]
Daina, A., Michielin, O. and Zoete, V. (2019) SwissTargetPrediction: Updated Data and New Features for Efficient Prediction of Protein Targets of Small Molecules. Nucleic Acids Research, 47, W357-W364. https://doi.org/10.1093/nar/gkz382
[27]
Yao, Z., Dong, J., Che, Y., Zhu, M., Wen, M., Wang, N., et al. (2016) TargetNet: A Web Service for Predicting Potential Drug-Target Interaction Profiling via Multi-Target SAR Models. Journal of Computer-Aided Molecular Design, 30, 413-424. https://doi.org/10.1007/s10822-016-9915-2
[28]
Zheng, G., Ma, Y., Zou, Y., Yin, A., Li, W. and Dong, D. (2017) HCMDB: The Human Cancer Metastasis Database. Nucleic Acids Research, 46, D950-D955. https://doi.org/10.1093/nar/gkx1008
[29]
Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., et al. (2016) The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current Protocols in Bioinformatics, 54, 1.30.1-1.30.33. https://doi.org/10.1002/cpbi.5
[30]
Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F. and Hamosh, A. (2014) Omim.org: Online Mendelian Inheritance in Man (OMIM®), an Online Catalog of Human Genes and Genetic Disorders. Nucleic Acids Research, 43, D789-D798. https://doi.org/10.1093/nar/gku1205
[31]
Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., et al. (2022) The STRING Database in 2023: Protein-Protein Association Networks and Functional Enrichment Analyses for Any Sequenced Genome of Interest. Nucleic Acids Research, 51, D638-D646. https://doi.org/10.1093/nar/gkac1000
[32]
Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. (2003) Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13, 2498-2504. https://doi.org/10.1101/gr.1239303
[33]
Wilkerson, M.D. and Hayes, D.N. (2010) ConsensusClusterPlus: A Class Discovery Tool with Confidence Assessments and Item Tracking. Bioinformatics, 26, 1572-1573. https://doi.org/10.1093/bioinformatics/btq170
[34]
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H. and Kanehisa, M. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research, 27, 29-34. https://doi.org/10.1093/nar/27.1.29
[35]
Tang, Z., Li, C., Kang, B., Gao, G., Li, C. and Zhang, Z. (2017) GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102. https://doi.org/10.1093/nar/gkx247
[36]
Goodsell, D.S., Zardecki, C., Di Costanzo, L., Duarte, J.M., Hudson, B.P., Persikova, I., et al. (2019) RCSB Protein Data Bank: Enabling Biomedical Research and Drug Discovery. Protein Science, 29, 52-65. https://doi.org/10.1002/pro.3730
[37]
El-Hachem, N., Haibe-Kains, B., Khalil, A., et al. (2017) AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study. Methods in Molecular Biology, 1598, 391-403. https://doi.org/10.1007/978-1-4939-6952-4_20
[38]
Baugh, E.H., Lyskov, S., Weitzner, B.D. and Gray, J.J. (2011) Real-Time PyMOL Visualization for Rosetta and PyRosetta. PLOS ONE, 6, e21931. https://doi.org/10.1371/journal.pone.0021931
[39]
Yang, J., Zhu, X., Yuan, P., Liu, J., Wang, B. and Wang, G. (2020) Efficacy of Traditional Chinese Medicine Combined with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis of Randomized Clinical Trials. Supportive Care in Cancer, 28, 3571-3579. https://doi.org/10.1007/s00520-020-05433-w
[40]
Wang, T., He, L., Zhang, M., Wang, S., Zhao, A., Chu, L., et al. (2018) Development of Improved Version of Quality of Life Assessment Instrument for Lung Cancer Patients Based on Traditional Chinese Medicine (QLASTCM-Lu). Chinese Journal of Integrative Medicine, 25, 831-836. https://doi.org/10.1007/s11655-018-2991-5
